Premium
Nephrogenic Systemic Fibrosis and Gadolinium‐Containing Radiological Contrast Agents: An Update
Author(s) -
Jalandhara N,
Arora R,
Batuman V
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.346
Subject(s) - nephrogenic systemic fibrosis , medicine , magnetic resonance imaging , gadolinium , fibrosis , pathology , radiology , chemistry , organic chemistry
Nephrogenic systemic fibrosis (NSF), originally described as “scleromyxedema‐like cutaneous disease,” is an entity that has emerged recently in patients with renal dysfunction. 1 NSF is a rare but severely disabling disease that manifests as fibrosis of skin and viscera. Numerous reports have highlighted an association between NSF and gadolinium (Gd)‐based contrast agents (GBCAs) used for magnetic resonance imaging. The exact mechanisms underlying this association are still under investigation. 2 , 3 There were apparently no reports of NSF prior to 1997, when the first cases were described. 1 Clinical Pharmacology & Therapeutics (2011) 89 6, 920–923. doi: 10.1038/clpt.2010.346